{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:01:51Z","timestamp":1792803711339,"version":"4.5.0"},"reference-count":285,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme","award":["MSCA-IF-2017, grant #786433"],"award-info":[{"award-number":["MSCA-IF-2017, grant #786433"]}]},{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme","award":["#R250-2017-1131"],"award-info":[{"award-number":["#R250-2017-1131"]}]},{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme","award":["#R368-2021-726"],"award-info":[{"award-number":["#R368-2021-726"]}]},{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme","award":["#R171-2014-591"],"award-info":[{"award-number":["#R171-2014-591"]}]},{"name":"Lundbeckfonden, Denmark","award":["MSCA-IF-2017, grant #786433"],"award-info":[{"award-number":["MSCA-IF-2017, grant #786433"]}]},{"name":"Lundbeckfonden, Denmark","award":["#R250-2017-1131"],"award-info":[{"award-number":["#R250-2017-1131"]}]},{"name":"Lundbeckfonden, Denmark","award":["#R368-2021-726"],"award-info":[{"award-number":["#R368-2021-726"]}]},{"name":"Lundbeckfonden, Denmark","award":["#R171-2014-591"],"award-info":[{"award-number":["#R171-2014-591"]}]},{"name":"Lundbeckfonden","award":["MSCA-IF-2017, grant #786433"],"award-info":[{"award-number":["MSCA-IF-2017, grant #786433"]}],"id":[{"id":"https:\/\/ror.org\/03hz8wd80","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lundbeckfonden","award":["#R250-2017-1131"],"award-info":[{"award-number":["#R250-2017-1131"]}],"id":[{"id":"https:\/\/ror.org\/03hz8wd80","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lundbeckfonden","award":["#R368-2021-726"],"award-info":[{"award-number":["#R368-2021-726"]}],"id":[{"id":"https:\/\/ror.org\/03hz8wd80","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lundbeckfonden","award":["#R171-2014-591"],"award-info":[{"award-number":["#R171-2014-591"]}],"id":[{"id":"https:\/\/ror.org\/03hz8wd80","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Defects in brain energy metabolism and proteopathic stress are implicated in age-related degenerative neuronopathies, exemplified by Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD). As the currently available drug regimens largely aim to mitigate cognitive decline and\/or motor symptoms, there is a dire need for mechanism-based therapies that can be used to improve neuronal function and potentially slow down the underlying disease processes. In this context, a new class of pharmacological agents that achieve improved glycaemic control via the glucagon-like peptide 1 (GLP-1) receptor has attracted significant attention as putative neuroprotective agents. The experimental evidence supporting their potential therapeutic value, mainly derived from cellular and animal models of AD and PD, has been discussed in several research reports and review opinions recently. In this review article, we discuss the pathological relevance of derangements in the neurovascular unit and the significance of neuron\u2013glia metabolic coupling in AD and PD. With this context, we also discuss some unresolved questions with regard to the potential benefits of GLP-1 agonists on the neurovascular unit (NVU), and provide examples of novel experimental paradigms that could be useful in improving our understanding regarding the neuroprotective mode of action associated with these agents.<\/jats:p>","DOI":"10.3390\/cells11132023","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T10:39:13Z","timestamp":1656153553000},"page":"2023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-1273","authenticated-orcid":false,"given":"Giulia","family":"Monti","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Aarhus University, H\u00f8egh-Guldbergs Gade 10, DK-8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-1772","authenticated-orcid":false,"given":"Diana","family":"Gomes Moreira","sequence":"additional","affiliation":[{"name":"VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Richner","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, H\u00f8egh-Guldbergs Gade 10, DK-8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henricus Antonius Maria","family":"Mutsaers","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, DK-8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-9097","authenticated-orcid":false,"given":"Nelson","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, H\u00f8egh-Guldbergs Gade 10, DK-8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-0070","authenticated-orcid":false,"given":"Asad","family":"Jan","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, H\u00f8egh-Guldbergs Gade 10, DK-8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/edrv.20.6.0385","article-title":"The Glucagon-like Peptides","volume":"20","author":"Kieffer","year":"1999","journal-title":"Endocr. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/joe.0.1380159","article-title":"Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns","volume":"138","author":"Elliott","year":"1993","journal-title":"J. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1210\/er.2016-1078","article-title":"Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance","volume":"37","author":"Pujadas","year":"2016","journal-title":"Endocr. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0014-5793(91)80182-3","article-title":"Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7\u201337) on a somatostatin secreting cell line","volume":"279","author":"Fehmann","year":"1991","journal-title":"FEBS Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1471-4159.2004.02914.x","article-title":"The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem","volume":"92","author":"Alvarez","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.molmet.2017.06.002","article-title":"Serotonergic modulation of the activity of GLP-1 producing neurons in the nucleus of the solitary tract in mouse","volume":"6","author":"Holt","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","article-title":"Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS","volume":"20","author":"Hamilton","year":"2009","journal-title":"Neuroreport"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-381517-0.00013-8","article-title":"Chapter Thirteen\u2014The Role of GLP-1 in Neuronal Activity and Neurodegeneration","volume":"Volume 84","author":"Litwack","year":"2010","journal-title":"Vitamins & Hormones"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1567205054367892","article-title":"Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer\u2019s disease","volume":"2","author":"Perry","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","article-title":"GLP-1 receptor activated insulin secretion from pancreatic beta-cells: Mechanism and glucose dependence","volume":"15","author":"Meloni","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1900\/RDS.2011.8.418","article-title":"GLP-1, the Gut-Brain, and Brain-Periphery Axes","volume":"8","author":"Cendrine","year":"2011","journal-title":"Rev. Diabet. Stud."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2337\/db16-0755","article-title":"Glucagon-like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight","volume":"66","author":"Anderberg","year":"2017","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases","volume":"221","author":"Holscher","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e3070","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: Are they all the same?","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management Of Endocrine Disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1038\/s41598-017-02838-2","article-title":"GLP-1 receptor signalling promotes beta-cell glucose metabolism via mTOR-dependent HIF-1alpha activation","volume":"7","author":"Carlessi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","unstructured":"Takei, Y., Ando, H., and Tsutsui, K. (2016). Subchapter 17C\u2014Glucagon-like Peptide-1. Handbook of Hormones, Academic Press."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/isl.1.3.9932","article-title":"GLP-1 protects \u03b2-cells against apoptosis by enhancing the activity of an IGF-2\/IGF1-receptor autocrine loop","volume":"1","author":"Cornu","year":"2009","journal-title":"Islets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.peptides.2017.12.002","article-title":"A role for Glucagon-like Peptide-1 in the regulation of beta-cell autophagy","volume":"100","author":"Arden","year":"2018","journal-title":"Peptides"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2337\/db16-1009","article-title":"Glucagon-like Peptide 1 Protects Pancreatic Beta-Cells from Death by Increasing Autophagic Flux and Restoring Lysosomal Function","volume":"66","author":"Zummo","year":"2017","journal-title":"Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbrc.2016.05.086","article-title":"GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK\/mTOR pathway","volume":"476","author":"He","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1677\/JOE-06-0148","article-title":"Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies","volume":"193","author":"Tsunekawa","year":"2007","journal-title":"J. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2337\/db09-0685","article-title":"Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB","volume":"58","author":"Cunha","year":"2009","journal-title":"Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2337\/db15-0084","article-title":"GLP-1 Cleavage Product Reverses Persistent ROS Generation after Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop","volume":"64","author":"Giacco","year":"2015","journal-title":"Diabetes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.coph.2009.09.003","article-title":"A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism","volume":"9","author":"Burcelin","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bcpt.12974","article-title":"Neuroprotective Mechanisms of Glucagon-like Peptide-1-Based Therapies in Ischaemic Stroke: A Systematic Review Based on Pre-Clinical Studies","volume":"122","author":"Marlet","year":"2018","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0271678X20952011","article-title":"Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: A systematic scoping review","volume":"41","author":"Maskery","year":"2021","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gray, F.o., Duyckaerts, C., De Girolami, U., Escourolle, R., and Gray, F.O. (2014). Escourolle & Poirier\u2019s Manual of Basic Neuropathology, Oxford University Press. [5th ed.].","DOI":"10.1093\/med\/9780199929054.001.0001"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson Disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","article-title":"Ageing and Parkinson\u2019s disease: Why is advancing age the biggest risk factor?","volume":"14","author":"Reeve","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Schapira, A.H.V. (2010). Parkinson\u2019s Disease, Oxford University Press.","DOI":"10.1093\/med\/9780199550630.001.0001"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","article-title":"Predictors of dementia in Parkinson disease: A prospective cohort study","volume":"83","author":"Anang","year":"2014","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of Neurodegenerative Diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer\u2019s Disease","volume":"164","author":"Karran","year":"2016","journal-title":"Cell"},{"key":"ref_49","first-page":"1","article-title":"Neuroanatomy and pathology of sporadic Parkinson\u2019s disease","volume":"Volume 201","author":"Braak","year":"2009","journal-title":"Advances in Anatomy Embryology Cell Biology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Li, Y., Chigurupati, S., Holloway, H.W., Mughal, M., Tweedie, D., Bruestle, D.A., Mattson, M.P., Wang, Y., Harvey, B.K., and Ray, B. (2012). Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032008"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","article-title":"Neuroprotective properties of GLP-1: Theoretical and practical applications","volume":"27","author":"Holst","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neurobiolaging.2004.09.022","article-title":"Oxidative damage as an early marker of Alzheimer\u2019s disease and mild cognitive impairment","volume":"26","author":"Beal","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","article-title":"Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson\u2019s disease","volume":"25","author":"Badawi","year":"2017","journal-title":"Inflammopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fcell.2019.00356","article-title":"Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury","volume":"7","author":"Bader","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP\/PS1\/Tau Triple Transgenic Mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Eakin, K., Li, Y., Chiang, Y.H., Hoffer, B.J., Rosenheim, H., Greig, N.H., and Miller, J.P. (2013). Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082016"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","article-title":"Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson\u2019s disease","volume":"1646","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/jcp.29204","article-title":"Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke","volume":"235","author":"He","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer\u2019s disease","volume":"19","author":"Li","year":"2010","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cmet.2013.11.002","article-title":"TNF-\u03b1 mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer\u2019s \u03b2-amyloid oligomers in mice and monkeys","volume":"18","author":"Lourenco","year":"2013","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.expneurol.2006.09.028","article-title":"Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy","volume":"203","author":"Perry","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","article-title":"Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3\u03b2 pathway in an amyloid \u03b2 protein induced alzheimer disease mouse model","volume":"783","author":"Qi","year":"2016","journal-title":"Eur. J. Pharm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11357-012-9464-0","article-title":"Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice","volume":"35","author":"Rachmany","year":"2013","journal-title":"Age"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101180","DOI":"10.1016\/j.molmet.2021.101180","article-title":"GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease","volume":"47","author":"Zheng","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2012.04.009","article-title":"Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats","volume":"34","author":"Han","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","article-title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease","volume":"495","author":"Cai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","article-title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2","volume":"511","author":"Zhou","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease","volume":"245","author":"Batista","year":"2018","journal-title":"J. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress","volume":"128","author":"Sharma","year":"2014","journal-title":"J. Neurochem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease","volume":"86","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Paladugu, L., Gharaibeh, A., Kolli, N., Learman, C., Hall, T.C., Li, L., Rossignol, J., Maiti, P., and Dunbar, G.L. (2021). Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020860"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"741923","DOI":"10.3389\/fnagi.2021.741923","article-title":"Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer\u2019s Disease and Type 2 Diabetes","volume":"13","author":"Herrera","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","article-title":"Lixisenatide rescues spatial memory and synaptic plasticity from amyloid \u03b2 protein-induced impairments in rats","volume":"277","author":"Cai","year":"2014","journal-title":"Neuroscience"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"113693","DOI":"10.1016\/j.expneurol.2021.113693","article-title":"An extended release GLP-1 analogue increases alpha-synuclein accumulation in a mouse model of prodromal Parkinson\u2019s disease","volume":"341","author":"Bergkvist","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: A randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav. Brain Res."},{"key":"ref_86","first-page":"A4519","article-title":"Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer\u00b4s disease\u2014Protocol for a controlled, randomized double-blinded trial","volume":"59","author":"Egefjord","year":"2012","journal-title":"Dan. Med. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: Study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A Pilot Study of Exenatide Actions in Alzheimer\u2019s Disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Dickson","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_92","first-page":"CD012990","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/db08-0799","article-title":"Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease","volume":"58","author":"Martin","year":"2009","journal-title":"Diabetes"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"15742","DOI":"10.1038\/s41598-019-52295-2","article-title":"GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome","volume":"9","author":"Seppa","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmet.2011.08.016","article-title":"Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation","volume":"14","author":"Allaman","year":"2011","journal-title":"Cell Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cercor\/6.1.50","article-title":"Cellular bases of brain energy metabolism and their relevance to functional brain imaging: Evidence for a prominent role of astrocytes","volume":"6","author":"Magistretti","year":"1996","journal-title":"Cereb. Cortex"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s11064-020-03005-2","article-title":"Fluid Brain Glycolysis: Limits, Speed, Location, Moonlighting, and the Fates of Glycogen and Lactate","volume":"45","author":"Barros","year":"2020","journal-title":"Neurochem. Res."},{"key":"ref_98","first-page":"2369","article-title":"Lactate Mediates the Effects of Exercise on Learning and Memory through SIRT1-Dependent Activation of Hippocampal Brain-Derived Neurotrophic Factor (BDNF)","volume":"39","author":"Khalifeh","year":"2019","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"825816","DOI":"10.3389\/fphys.2021.825816","article-title":"Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives","volume":"12","author":"Beard","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s12035-015-9672-6","article-title":"Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery","volume":"54","author":"Patching","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","article-title":"Sugar for the brain: The role of glucose in physiological and pathological brain function","volume":"36","author":"Mergenthaler","year":"2013","journal-title":"Trends Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2012.08.019","article-title":"Synaptic energy use and supply","volume":"75","author":"Harris","year":"2012","journal-title":"Neuron"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuron.2017.07.030","article-title":"The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease","volume":"96","author":"Iadecola","year":"2017","journal-title":"Neuron"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1460-9568.2010.07584.x","article-title":"The role(s) of astrocytes and astrocyte activity in neurometabolism, neurovascular coupling, and the production of functional neuroimaging signals","volume":"33","author":"Figley","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev.neuro.29.051605.112819","article-title":"Brain work and brain imaging","volume":"29","author":"Raichle","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41593-018-0234-x","article-title":"The role of brain vasculature in neurodegenerative disorders","volume":"21","author":"Sweeney","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Carare","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1152\/japplphysiol.00319.2006","article-title":"How the body controls brain temperature: The temperature shielding effect of cerebral blood flow","volume":"101","author":"Zhu","year":"2006","journal-title":"J. Appl. Physiol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Newman, L.A., Korol, D.L., and Gold, P.E. (2011). Lactate produced by glycogenolysis in astrocytes regulates memory processing. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028427"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_111","first-page":"73","article-title":"Mechanisms Mediating Functional Hyperemia in the Brain","volume":"24","author":"Nippert","year":"2018","journal-title":"Neurosci. A Rev. J. Bringing Neurobiol. Neurol. Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/nn.4428","article-title":"Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles","volume":"19","author":"Mishra","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nn980","article-title":"Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation","volume":"6","author":"Zonta","year":"2003","journal-title":"Nat. Neurosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1523\/JNEUROSCI.1782-16.2016","article-title":"Glial Cell Calcium Signaling Mediates Capillary Regulation of Blood Flow in the Retina","volume":"36","author":"Biesecker","year":"2016","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_115","first-page":"H1703","article-title":"Role of adenosine in regulation of regional cerebral blood flow in sensory cortex","volume":"259","author":"Ko","year":"1990","journal-title":"Am. J. Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1113\/jphysiol.2013.267294","article-title":"Purinergic control of vascular tone in the retina","volume":"592","author":"Kur","year":"2014","journal-title":"J. Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s43587-021-00043-5","article-title":"Healthy aging and the blood-brain barrier","volume":"1","author":"Banks","year":"2021","journal-title":"Nat. Aging"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/ncomms5196","article-title":"Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells","volume":"5","author":"Watkins","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nn2003","article-title":"Glial regulation of the cerebral microvasculature","volume":"10","author":"Iadecola","year":"2007","journal-title":"Nat. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nut.2010.07.021","article-title":"Brain fuel metabolism, aging, and Alzheimer\u2019s disease","volume":"27","author":"Cunnane","year":"2011","journal-title":"Nutrition"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archneurol.2011.157","article-title":"Ecology of the aging human brain","volume":"68","author":"Sonnen","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neulet.2005.09.025","article-title":"Neurophysiological correlates of age-related changes in working memory capacity","volume":"392","author":"Mattay","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_123","unstructured":"Riddle, D.R. (2007). Frontiers in Neuroscience. Changes in Cognitive Function in Human Aging. Brain Aging: Models, Methods, and Mechanisms, Taylor & Francis Group, LLC."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1212\/WNL.43.1_Part_1.192","article-title":"Quantitative synaptic alterations in the human neocortex during normal aging","volume":"43","author":"Masliah","year":"1993","journal-title":"Neurology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbadis.2015.12.016","article-title":"Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer\u2019s disease","volume":"1862","author":"Nelson","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neuroimage.2015.10.085","article-title":"White matter and memory in healthy adults: Coupled changes over two years","volume":"131","author":"Bender","year":"2016","journal-title":"NeuroImage"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"117591","DOI":"10.1016\/j.neuroimage.2020.117591","article-title":"Relationship between the disrupted topological efficiency of the structural brain connectome and glucose hypometabolism in normal aging","volume":"226","author":"Bi","year":"2021","journal-title":"NeuroImage"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(04)15441-X","article-title":"Imaging cerebral atrophy: Normal ageing to Alzheimer\u2019s disease","volume":"363","author":"Fox","year":"2004","journal-title":"Lancet"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1523\/JNEUROSCI.23-08-03295.2003","article-title":"Longitudinal magnetic resonance imaging studies of older adults: A shrinking brain","volume":"23","author":"Resnick","year":"2003","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cercor\/bhh032","article-title":"Thinning of the cerebral cortex in aging","volume":"14","author":"Salat","year":"2004","journal-title":"Cereb. Cortex"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wrigglesworth, J., Ward, P., Harding, I.H., Nilaweera, D., Wu, Z., Woods, R.L., and Ryan, J. (2021). Factors associated with brain ageing\u2014A systematic review. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02331-4"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00401-008-0352-8","article-title":"Morphometry of the human substantia nigra in ageing and Parkinson\u2019s disease","volume":"115","author":"Rudow","year":"2008","journal-title":"Acta Neuropathol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2990.2002.00393.x","article-title":"Ageing of substantia nigra in humans: Cell loss may be compensated by hypertrophy","volume":"28","author":"Cabello","year":"2002","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","article-title":"alpha-Synucleinopathy phenotypes","volume":"20","author":"McCann","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/mds.22801","article-title":"A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson\u2019s disease","volume":"25","author":"Chan","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1212\/WNL.0b013e3182897103","article-title":"Neural reserve, neuronal density in the locus ceruleus, and cognitive decline","volume":"80","author":"Wilson","year":"2013","journal-title":"Neurology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"530219","DOI":"10.3389\/fnins.2020.530219","article-title":"Metabolic Dysregulation Contributes to the Progression of Alzheimer\u2019s Disease","volume":"14","author":"Yan","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","article-title":"Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study","volume":"5","author":"Kivipelto","year":"2006","journal-title":"Lancet. Neurol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaneurol.2018.1123","article-title":"Interactive Associations of Vascular Risk and \u03b2-Amyloid Burden with Cognitive Decline in Clinically Normal Elderly Individuals: Findings from the Harvard Aging Brain Study","volume":"75","author":"Rabin","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/YCO.0000000000000239","article-title":"Interaction between cerebrovascular disease and Alzheimer pathology","volume":"29","author":"Saito","year":"2016","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/JAD-2012-120364","article-title":"High prevalence of cerebral microbleeds at 7Tesla MRI in patients with early Alzheimer\u2019s disease","volume":"31","author":"Brundel","year":"2012","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-130542","article-title":"Multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer\u2019s disease","volume":"38","author":"Heringa","year":"2014","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/bmm.15.101","article-title":"Cerebral microbleeds as a biomarker in Alzheimer\u2019s disease? A review in the field","volume":"10","author":"Shams","year":"2016","journal-title":"Biomark. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3174\/ajnr.A3332","article-title":"Prevalence and topography of small hypointense foci suggesting microbleeds on 3T susceptibility-weighted imaging in various types of dementia","volume":"34","author":"Uetani","year":"2013","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00415-016-8220-2","article-title":"Cerebral microbleeds in early Alzheimer\u2019s disease","volume":"263","author":"Poliakova","year":"2016","journal-title":"J. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.0000000000000285","article-title":"Incidence of cerebral microbleeds in preclinical Alzheimer disease","volume":"82","author":"Yates","year":"2014","journal-title":"Neurology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/01.wnl.0000307750.41970.d9","article-title":"Prevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study","volume":"70","author":"Vernooij","year":"2008","journal-title":"Neurology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000113681","article-title":"Pathophysiology of neuronal energy crisis in Alzheimer\u2019s disease","volume":"5","year":"2008","journal-title":"Neuro-Degener. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00401-015-1522-0","article-title":"Cerebrovascular disease in ageing and Alzheimer\u2019s disease","volume":"131","author":"Love","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1161\/01.STR.0000143317.70478.b3","article-title":"Atherosclerosis of cerebral arteries in Alzheimer disease","volume":"35","author":"Roher","year":"2004","journal-title":"Stroke"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(99)00641-8","article-title":"Blood vessels change in the mesencephalon of patients with Parkinson\u2019s disease","volume":"353","author":"Faucheux","year":"1999","journal-title":"Lancet"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1750-3639.2012.00628.x","article-title":"Vascular degeneration in Parkinson\u2019s disease","volume":"23","author":"Guan","year":"2013","journal-title":"Brain Pathol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1177\/0271678X16688919","article-title":"Structural and physiological neurovascular changes in idiopathic Parkinson\u2019s disease and its clinical phenotypes","volume":"37","author":"Vidyasagar","year":"2017","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00429-010-0246-0","article-title":"Cortical hypometabolism and hypoperfusion in Parkinson\u2019s disease is extensive: Probably even at early disease stages","volume":"214","author":"Borghammer","year":"2010","journal-title":"Brain Struct. Funct."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.neuroimage.2011.10.033","article-title":"Cortical hypoperfusion in Parkinson\u2019s disease assessed using arterial spin labeled perfusion MRI","volume":"59","author":"Mengual","year":"2012","journal-title":"NeuroImage"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00406-011-0226-2","article-title":"Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer\u2019s disease measured by pulsed arterial spin labeling MRI","volume":"262","author":"Alexopoulos","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1148\/radiol.2503080751","article-title":"Mild cognitive impairment and alzheimer disease: Patterns of altered cerebral blood flow at MR imaging","volume":"250","author":"Dai","year":"2009","journal-title":"Radiology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1567205010666131119234845","article-title":"Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer\u2019s disease","volume":"11","author":"Lagro","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10571-015-0261-z","article-title":"The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer\u2019s Disease","volume":"36","author":"Hays","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.20493","article-title":"Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam Study","volume":"57","author":"Ruitenberg","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Costantini, L.C., Barr, L.J., Vogel, J.L., and Henderson, S.T. (2008). Hypometabolism as a therapeutic target in Alzheimer\u2019s disease. BMC Neurosci., 9.","DOI":"10.1186\/1471-2202-9-S2-S16"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2017.07.010","article-title":"Loss of Brain Aerobic Glycolysis in Normal Human Aging","volume":"26","author":"Goyal","year":"2017","journal-title":"Cell Metab."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/jcbfm.1991.65","article-title":"Diminished glucose transport in Alzheimer\u2019s disease: Dynamic PET studies","volume":"11","author":"Jagust","year":"1991","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","article-title":"FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer\u2019s disease","volume":"36","author":"Mosconi","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"583931","DOI":"10.1155\/2015\/583931","article-title":"Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer\u2019s Disease and Mild Cognitive Impairment: MRI and (18)F-FDG PET Quantitative Analysis Using FreeSurfer","volume":"2015","author":"Bailly","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ana.410420114","article-title":"Metabolic reduction in the posterior cingulate cortex in very early Alzheimer\u2019s disease","volume":"42","author":"Minoshima","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.2635903100","article-title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer\u2019s dementia","volume":"101","author":"Reiman","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3233\/JAD-170158","article-title":"A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer\u2019s Disease in a Clinical Setting","volume":"59","author":"Iaccarino","year":"2017","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5483\/BMBRep.2009.42.8.475","article-title":"Insulin resistance and Alzheimer\u2019s disease","volume":"42","year":"2009","journal-title":"BMB Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2004.02.049","article-title":"Glucose metabolism and insulin receptor signal transduction in Alzheimer disease","volume":"490","author":"Hoyer","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer\u2019s disease and related disorders: Mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1073\/pnas.0709259105","article-title":"Alzheimer\u2019s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons","volume":"105","author":"Liang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1749-6632.1997.tb48476.x","article-title":"Decreased brain glucose metabolism in microvessels from patients with Alzheimer\u2019s disease","volume":"826","author":"Marcus","year":"1997","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fnagi.2017.00345","article-title":"Insulin Resistance and Alzheimer\u2019s Disease: Bioenergetic Linkages","volume":"9","author":"Neth","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JAD-2005-8304","article-title":"Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer\u2019s disease: Link to brain reductions in acetylcholine","volume":"8","author":"Rivera","year":"2005","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.neuron.2008.04.014","article-title":"Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo","volume":"58","author":"Chiu","year":"2008","journal-title":"Neuron"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1073\/pnas.0809158106","article-title":"Protection of synapses against Alzheimer\u2019s-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers","volume":"106","author":"Vieira","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/j.1464-5491.2011.03464.x","article-title":"Insulin resistance and pathological brain ageing","volume":"28","author":"Cholerton","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1042\/BST0390891","article-title":"Diabetes as a risk factor for Alzheimer\u2019s disease: Insulin signalling impairment in the brain as an alternative model of Alzheimer\u2019s disease","volume":"39","author":"Holscher","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"ref_184","first-page":"287","article-title":"Diabetes mellitus, dementia, and cognitive function in older persons","volume":"10","author":"Arvanitakis","year":"2006","journal-title":"J. Nutr. Health Aging"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archneurol.2010.225","article-title":"Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes","volume":"68","author":"Baker","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2337\/db14-1507","article-title":"Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease","volume":"64","author":"Willette","year":"2015","journal-title":"Diabetes"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00005072-199501000-00005","article-title":"Functional alterations in Alzheimer\u2019s disease: Decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone","volume":"54","author":"Harr","year":"1995","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0197-4580(97)00111-5","article-title":"GLUT-1 expression in the cerebra of patients with Alzheimer\u2019s disease","volume":"18","author":"Mooradian","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ana.410350507","article-title":"Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer\u2019s disease","volume":"35","author":"Simpson","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneur.1988.00520320022009","article-title":"Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer\u2019s disease","volume":"45","author":"Gibson","year":"1988","journal-title":"Arch. Neurol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1471-4159.1992.tb09439.x","article-title":"Brain cytochrome oxidase in Alzheimer\u2019s disease","volume":"59","author":"Kish","year":"1992","journal-title":"J. Neurochem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2011.12.008","article-title":"Dementia is associated with Insulin Resistance in patients with Parkinson\u2019s Disease","volume":"315","author":"Bosco","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","article-title":"Shared dysregulated pathways lead to Parkinson\u2019s disease and diabetes","volume":"19","author":"Santiago","year":"2013","journal-title":"Trends Mol. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.parkreldis.2014.02.016","article-title":"Diabetes is associated with postural and cognitive domains in Parkinson\u2019s disease. Results from a single-center study","volume":"20","author":"Giuntini","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019s disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","article-title":"Dysregulation of glucose metabolism is an early event in sporadic Parkinson\u2019s disease","volume":"35","author":"Dunn","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-019-01971-8","article-title":"Translational control in brain pathologies: Biological significance and therapeutic opportunities","volume":"137","author":"Delaidelli","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1111\/j.1742-4658.2005.04833.x","article-title":"Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer\u2019s disease brain","volume":"272","author":"Li","year":"2005","journal-title":"FEBS J."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00401-010-0759-x","article-title":"AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer\u2019s disease and other tauopathies","volume":"121","author":"Vingtdeux","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40478-018-0554-9","article-title":"Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity","volume":"6","author":"Jan","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00401-016-1634-1","article-title":"eEF2K inhibition blocks Abeta42 neurotoxicity by promoting an NRF2 antioxidant response","volume":"133","author":"Jan","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1097\/00001756-200212200-00011","article-title":"Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer\u2019s disease","volume":"13","author":"Chang","year":"2002","journal-title":"Neuroreport"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Helmstadter, J., Keppeler, K., Aust, F., Kuster, L., Frenis, K., Filippou, K., Vujacic-Mirski, K., Tsohataridis, S., Kalinovic, S., and Kroller-Schon, S. (2021). GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation. Antioxidants, 10.","DOI":"10.3390\/antiox10081175"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.2040-1124.2010.00018.x","article-title":"Molecular mechanisms of diabetic vascular complications","volume":"1","author":"Kitada","year":"2010","journal-title":"J. Diabetes Investig."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","article-title":"RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages","volume":"61","author":"Kokkola","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0002-9440(10)65659-3","article-title":"Advanced glycation end products in Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"153","author":"Sasaki","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","article-title":"Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease","volume":"32","author":"Srikanth","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/cercor\/bhh123","article-title":"Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer\u2019s disease brains","volume":"15","author":"Luth","year":"2005","journal-title":"Cereb. Cortex"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"31446","DOI":"10.1039\/C6CP05041G","article-title":"Glycation induces conformational changes in the amyloid-beta peptide and enhances its aggregation propensity: Molecular insights","volume":"18","author":"Jana","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0197-4580(95)02002-0","article-title":"Memory improvement following induced hyperinsulinemia in Alzheimer\u2019s disease","volume":"17","author":"Craft","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Sartorius, T., Peter, A., Heni, M., Maetzler, W., Fritsche, A., Haring, H.U., and Hennige, A.M. (2015). The brain response to peripheral insulin declines with age: A contribution of the blood-brain barrier?. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126804"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2014Is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00193951","article-title":"Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer\u2019s disease","volume":"425","author":"Horwood","year":"1994","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nn.3966","article-title":"GLUT1 reductions exacerbate Alzheimer\u2019s disease vasculo-neuronal dysfunction and degeneration","volume":"18","author":"Winkler","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jnr.22596","article-title":"Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia","volume":"89","author":"Lee","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1523\/JNEUROSCI.3579-15.2016","article-title":"Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance","volume":"36","author":"Reiner","year":"2016","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function","volume":"31","author":"Timper","year":"2020","journal-title":"Cell Metab."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrn.2018.19","article-title":"Lactate in the brain: From metabolic end-product to signalling molecule","volume":"19","author":"Magistretti","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1523\/JNEUROSCI.0756-16.2017","article-title":"Respiration-Deficient Astrocytes Survive As Glycolytic Cells In Vivo","volume":"37","author":"Supplie","year":"2017","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e71424","DOI":"10.7554\/eLife.71424","article-title":"Lactate is an energy substrate for rodent cortical neurons and enhances their firing activity","volume":"10","author":"Karagiannis","year":"2021","journal-title":"eLife"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"10625","DOI":"10.1073\/pnas.91.22.10625","article-title":"Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization","volume":"91","author":"Pellerin","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000343657","article-title":"New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: Extended benefit after intracerebroventricular injection and efficacy of intravenous administration","volume":"34","author":"Berthet","year":"2012","journal-title":"Cerebrovasc. Dis."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.cell.2011.02.018","article-title":"Astrocyte-neuron lactate transport is required for long-term memory formation","volume":"144","author":"Suzuki","year":"2011","journal-title":"Cell"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s12264-020-00587-3","article-title":"Dynamic Variations in Brain Glycogen are Involved in Modulating Isoflurane Anesthesia in Mice","volume":"36","author":"Fan","year":"2020","journal-title":"Neurosci. Bull."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0006-8993(01)02640-3","article-title":"Activated astrocytes with glycogen accumulation in ischemic penumbra during the early stage of brain infarction: Immunohistochemical and electron microscopic studies","volume":"909","author":"Kajihara","year":"2001","journal-title":"Brain Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abbi.1997.9951","article-title":"Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle","volume":"341","author":"Alcantara","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0303-7207(03)00146-1","article-title":"Cell signalling of the GLP-1 action in rat liver","volume":"204","author":"Redondo","year":"2003","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00702-013-1149-z","article-title":"A further update on the role of excitotoxicity in the pathogenesis of Parkinson\u2019s disease","volume":"121","author":"Ambrosi","year":"2014","journal-title":"J. Neural. Transm."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"110142","DOI":"10.1016\/j.celrep.2021.110142","article-title":"Stepwise disassembly of GABAergic synapses during pathogenic excitotoxicity","volume":"37","author":"Garcia","year":"2021","journal-title":"Cell Rep."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/36.6.2896676","article-title":"Cellular and subcellular immunolocalization of L-glutamate decarboxylase in rat pancreatic islets","volume":"36","author":"Garry","year":"1988","journal-title":"J. Histochem. Cytochem."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2337\/diab.40.11.1365","article-title":"Structural and functional considerations of GABA in islets of Langerhans. Beta-cells and nerves","volume":"40","author":"Sorenson","year":"1991","journal-title":"Diabetes"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/341233a0","article-title":"Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels","volume":"341","author":"Rorsman","year":"1989","journal-title":"Nature"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"E1201","DOI":"10.1152\/ajpendo.00459.2006","article-title":"Glucagon-like peptide-1 stimulates GABA formation by pancreatic beta-cells at the level of glutamate decarboxylase","volume":"292","author":"Wang","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2337\/diabetes.53.4.1038","article-title":"Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells","volume":"53","author":"Wendt","year":"2004","journal-title":"Diabetes"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0896-6273(03)00356-8","article-title":"Control of synaptic strength, a novel function of Akt","volume":"38","author":"Wang","year":"2003","journal-title":"Neuron"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"eaay8071","DOI":"10.1126\/scitranslmed.aay8071","article-title":"GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats","volume":"12","author":"Fortin","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Laurindo, L.F., Barbalho, S.M., Guiguer, E.L., da Silva Soares de Souza, M., de Souza, G.A., Fidalgo, T.M., Araujo, A.C., de Souza Gonzaga, H.F., de Bortoli Teixeira, D., and de Oliveira Silva Ullmann, T. (2022). GLP-1a: Going Beyond Traditional Use. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020739"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","article-title":"Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that Exendin-4 is a Ligand of Brain GLP-1 Binding Sites","volume":"7","author":"Larsen","year":"1995","journal-title":"Eur. J. Neurosci."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","article-title":"Body fluid cytokine levels in mild cognitive impairment and Alzheimer\u2019s disease: A comparative overview","volume":"50","author":"Brosseron","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2174\/1567205014666170317113606","article-title":"Impact of Cytokines and Chemokines on Alzheimer\u2019s Disease Neuropathological Hallmarks","volume":"14","author":"Domingues","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","article-title":"The blood-brain barrier in systemic infection and inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Attems, J., and Jellinger, K.A. (2014). The overlap between vascular disease and Alzheimer\u2019s disease--lessons from pathology. BMC Med., 12.","DOI":"10.1186\/s12916-014-0206-2"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic Encephalopathy","volume":"375","author":"Wijdicks","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2021.09.025","article-title":"Uremic encephalopathy","volume":"101","author":"Rosner","year":"2022","journal-title":"Kidney Int."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11011-020-00623-1","article-title":"Linking chronic kidney disease and Parkinson\u2019s disease: A literature review","volume":"36","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jhep.2012.11.043","article-title":"Cirrhosis-related Parkinsonism: Prevalence, mechanisms and response to treatments","volume":"58","author":"Tryc","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaneurol.2017.3229","article-title":"Association of Nonalcoholic Fatty Liver Disease with Lower Brain Volume in Healthy Middle-Aged Adults in the Framingham Study","volume":"75","author":"Weinstein","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11011-020-00561-y","article-title":"Association between chronic kidney disease and Alzheimer\u2019s disease: An update","volume":"35","author":"Zhang","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41581-020-0266-9","article-title":"Mechanisms of cognitive dysfunction in CKD","volume":"16","author":"Viggiano","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Collaboration","year":"2020","journal-title":"Lancet"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jocn.2003.10.009","article-title":"Genetics and Parkinson\u2019s disease","volume":"11","author":"Cordato","year":"2004","journal-title":"J. Clin. Neurosci."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1007\/s11064-017-2384-8","article-title":"Cytochrome P450 2D6 and Parkinson\u2019s Disease: Polymorphism, Metabolic Role, Risk and Protection","volume":"42","author":"Mishra","year":"2017","journal-title":"Neurochem. Res."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1517\/17425250902973703","article-title":"The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat","volume":"5","author":"Wojcikowski","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., and Targher, G. (2021). Glucagon-like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11020073"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00069.2016","article-title":"Hepatic functions of GLP-1 and its based drugs: Current disputes and perspectives","volume":"311","author":"Jin","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD","volume":"107","author":"Cusi","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.003","article-title":"Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11892-022-01461-4","article-title":"Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists","volume":"22","author":"Cohen","year":"2022","journal-title":"Curr. Diab. Rep."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00424-012-1102-2","article-title":"The brain renin-angiotensin system: A diversity of functions and implications for CNS diseases","volume":"465","author":"Wright","year":"2013","journal-title":"Pflug. Arch."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease","volume":"26","author":"Toblli","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"6920620","DOI":"10.1155\/2018\/6920620","article-title":"Liraglutide Enhances the Activity of the ACE-2\/Ang(1-7)\/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A","volume":"2018","author":"Fandino","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1210\/en.2014-1685","article-title":"Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats","volume":"156","author":"Moya","year":"2015","journal-title":"Endocrinology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-019-02098-6","article-title":"ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"139","author":"Evans","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcp.2018.01.047","article-title":"Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor\/PI3K\/Akt\/BDNF pathway and inhibition of angiotensin II type-1 receptor\/NF-kappaB axis","volume":"151","author":"Rabie","year":"2018","journal-title":"Biochem. Pharm."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuropharm.2013.03.025","article-title":"Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke","volume":"71","author":"Regenhardt","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-022-00522-2","article-title":"Microbiota in neuroinflammation and synaptic dysfunction: A focus on Alzheimer\u2019s disease","volume":"17","author":"Bairamian","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","article-title":"Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation","volume":"7","author":"Romano","year":"2021","journal-title":"NPJ Parkinsons Dis."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2337\/dc10-0556","article-title":"Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded?","volume":"33","author":"Musso","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson\u2019s disease: Development and distribution of alpha-synuclein pathology","volume":"42","author":"Braak","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Jan, A., Goncalves, N.P., Vaegter, C.B., Jensen, P.H., and Ferreira, N. (2021). The Prion-like Spreading of Alpha-Synuclein in Parkinson\u2019s Disease: Update on Models and Hypotheses. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158338"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40478-021-01131-8","article-title":"Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain","volume":"9","author":"Ferreira","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"fcab104","DOI":"10.1093\/braincomms\/fcab104","article-title":"Prodromal neuroinvasion of pathological alpha-synuclein in brainstem reticular nuclei and white matter lesions in a model of alpha-synucleinopathy","volume":"3","author":"Ferreira","year":"2021","journal-title":"Brain Commun."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"10732","DOI":"10.1073\/pnas.1321785111","article-title":"Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice","volume":"111","author":"Sacino","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-019-02040-w","article-title":"Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats","volume":"138","author":"Ferreira","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Kuthati, Y., Rao, V.N., Busa, P., and Wong, C.S. (2021). Teneligliptin Exerts Antinociceptive Effects in Rat Model of Partial Sciatic Nerve Transection Induced Neuropathic Pain. Antioxidants, 10.","DOI":"10.3390\/antiox10091438"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-neuro-071013-014111","article-title":"Coupling mechanism and significance of the BOLD signal: A status report","volume":"37","author":"Hillman","year":"2014","journal-title":"Annu. Rev. Neurosci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/13\/2023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:22Z","timestamp":1760139502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/13\/2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":285,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cells11132023"],"URL":"https:\/\/doi.org\/10.3390\/cells11132023","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]}}}